logo

For the Inventor, By the Inventor

Shiga, Japan

Takara Bio Inc.


USPTO Granted Patents = 150

% Expired Patents = 64.0



Trademarks = 17

Forward Citations = 488

Loading Chart...
Loading Chart...

237 inventors (with patents filed for the assignee):

goldMedal Ikunoshin Kato (85 out of 210 patents)

silverMedal Takashi Uemori (33 out of 44 patents)

bronzeMedal Junichi Mineno (29 out of 29 patents)

4.  Hiroaki Sagawa (27 out of 45 patents)

5.  Kiyozo Asada (22 out of 47 patents)

6.  Tatsuji Enoki (21 out of 33 patents)

7.  Hiroyuki Mukai (20 out of 29 patents)

8.  Hiroshi Shiku (12 out of 24 patents)

9.  Hikaru Takakura (12 out of 15 patents)

10.  Takeshi Sakai (11 out of 51 patents)

11.  Hideto Chono (10 out of 13 patents)

12.  Nobuto Koyama (10 out of 37 patents)

13.  Eiji Kobayashi (9 out of 36 patents)

14.  Yoshimi Sato (9 out of 12 patents)

15.  Jun Tomono (9 out of 14 patents)


Core Competencies:
Nucleic Acid
AAV Variant
DNA Polymerase
Stem Cell Production
Chimeric Antigen Receptor
Endonuclease
RNA Detection
Cytotoxic T Lymphocyte
Gene Transfer
Viral Particles
Pluripotent Stem Cells
Nucleic Acid Amplification

150 patents:

1. 12673097 - IMPROVED DNA VACCINE FOR SARS-COV-2 (2026-07-07),
2. 12606845 - METHOD FOR PRODUCING NUCLEIC ACID-ENCAPSULATED AAV HOLLOW PARTICLE (2026-04-21),
3. 12480132 - HEAT RESISTANT MISMATCH ENDONUCLEASE VARIANT (2025-11-25),
4. 12421526 - AAV mutant having brain-targeting property (2025-09-23),
5. 12359177 - DNA polymerase mutant suited to nucleic acid amplification from RNA (2025-07-15),
6. 12018294 - DNA polymerase mutant suited to nucleic acid amplification from RNA (2024-06-25),
7. 12018276 - Lymphocyte production method (2024-06-25),
8. 11999972 - Fibronectin fragment to be used for stem cell production (2024-06-04),
9. 11572580 - Oligonucleotide preservation method (2023-02-07),
10. 11473057 - Method for obtaining microglia from pluripotent stem cells (2022-10-18),
11. 11225643 - Method for producing endothelial cells (2022-01-18),
12. 11220677 - Heat-resistant reverse transcriptase mutant (2022-01-11),
13. 11046939 - DNA polymerase variant (2021-06-29),
14. 11028131 - Mutant of adeno-associated virus (AAV) capsid protein (2021-06-08),
15. 10975415 - Methods of utilizing thermostable mismatch endonuclease (2021-04-13),
Company Overview
Takara Bio Inc., headquartered in Shiga, Japan, specializes in nucleic acid technology, focusing on the development and manufacturing of innovative solutions for genetic research and biotechnology applications. The company is known for its expertise in areas such as DNA polymerase, AAV variants, and stem cell production, contributing significantly to advancements in gene therapy and molecular biology. Takara Bio also engages in the production of tools for RNA detection and the development of chimeric antigen receptors, enhancing the capabilities of cytotoxic T lymphocytes in therapeutic contexts.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

150 Patents

#3 in Shiga

#858 in Japan

#5,448 in the World

Shiga, JP
Shiga, Japan

Takara Bio Inc.

Forward Citations = 488

237 inventors:

goldMedal Ikunoshin Kato (85 out of 210 patents)

silverMedal Takashi Uemori (33 out of 44 patents)

bronzeMedal Junichi Mineno (29 out of 29 patents)

4.  Hiroaki Sagawa (27 out of 45 patents)

5.  Kiyozo Asada (22 out of 47 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Takara Bio Inc.. Retrieved from https://idiyas.com/company/takara-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…